Cresco Labs swings to Q2 FY26 net income of USD 15.37 million; revenue rises 15% sequentially to USD 173 million
Margins and expenses
Adjusted EBITDA (non-GAAP) climbed 20% sequentially to USD 40 million, lifting the adjusted margin to 22.8% from 21.7%.
SG&A rose to USD 63 million, while adjusted SG&A (non-GAAP) increased to USD 55 million. The company said costs reflected M&A and uplisting preparedness.
Q2 results and profitability
Cresco Labs posted Q2 revenue of USD 173 million, up 15% sequentially. Net income swung to USD 15.37 million from a loss.
Balance sheet and management commentary
Cash and restricted cash totaled USD 67 million. The senior secured term loan stood at USD 311 million, with a USD 19 million mortgage loan.
Management cited improved gross profit dollars at acquired Pennsylvania dispensaries and said federal rescheduling could boost economics by removing 280E.
